- Chinese Exports Slump, Investment Offers Hope
- HSBC's Chief Discusses $18.3 Billion Rights Issue

- Japan Wholesale Prices Slide, Deflation Beckons
- UBS Raises 2008 Loss After Charges Including US Fine
- Citi Hopes Support Asia Stocks But China Weighs
- Madoff Set to Plead Guilty; No Plea Deal in Place
- You Are There: Loving the Madoff Cam
- Citigroup Sparks Big Rally, But the Pros Are Skeptical
- Citigroup Will Have To Sell More Assets: Whitney
- Lightning Round: Kellogg, Goldman Sachs, Las Vegas Sands and More
- Lightning Round OT: Qualcomm, MBIA and More
- Buy Bank of America?
- Cramer's Call on Hershey
- Cramer: Why This Rally Will Continue
- Your First Move For Wednesday March 11th
- Web Extra: Playing With Foreign Cars
- What's The TALF Trade?
- Pops & Drops: Alcoa, Wells Fargo...
- SKorea wants to conclude Qualcomm probe soon
- UBS revises 2008 loss to nearly 21BN Swiss francs
- Aer Lingus falls into red, forecasts '09 loss too
- Cathay Pacific suffers $1.1 billion loss for 2008
- Revenues and patrons up at Missouri casinos
- Pilgrim's Pride says no grower bias
- Delta and United plan fewer international flights
- Salmonella recall could cost peanut producers $1B
- Senator seeks probe of posthumous debt collection
WELLSBURG, W.Va. - State officials say a judge has fined health care products maker Johnson & Johnson and a subsidiary nearly $4.5 million for sending misleading information to West Virginia physicians about two prescription drugs.
Brooke County Circuit Judge Martin Gaughan sided with state Attorney General Darrell McGraw.
Gaughan says the defendants sent brochures on the narcotic pain patch Duragesic that the Food and Drug Administration had twice warned contained false or misleading statements.
In his Feb. 25 ruling, Gaughan also said the defendants' November 2003 letter on schizophrenia drug Risperdal intentionally modified the FDA's warning language and misled health care professionals.
Johnson & Johnson says it's disappointed and will seek a new trial.



